Connect evidence with understanding
Move beyond individual publications by exploring
evidence in its broader scientific context.
ARC connects individual research findings to the broader scientific landscape, helping researchers understand evidence with greater depth, context, and clarity.
OVERVIEW
WHAT YOU’LL EXPLORE
Examine evidence across contexts, perspectives, and formats to build a more complete understanding of scientific topics and their real-world implications.
In Alabama, recommending a research-grade peptide is the practice of medicine, and a signed waiver does not cure it.
The prohibition reaches further than prescribing, the consent form practitioners rely on is declared ineffective, and the board's stated reason…
Retatrutide meets primary endpoint in first pivotal obesity trial
Eli Lilly reported topline results from TRIUMPH-1, the first Phase 3 trial in retatrutide's obesity programme to read out.
A certificate of analysis looks the same whether or not the test on it was accredited.
Research Fundamentals covers what each analytical method measures. This is the separate question of what the document establishes: who tested,…
An observation establishes what happened. It does not establish what it means.
The most consequential error in independent work is rarely a bad measurement. It is a record that states a conclusion…
A verifier cannot sell what the verification serves
A trade association exists partly to balance competing commercial interests. ARC has no mandate to do that and no machinery…
Growing up
Where independent research has been, where it is now, and what maturing actually requires.
Why a result from one compound in a class does not carry to the next.
Receptor profile is the reason most often given, and it is the weakest of the five. The other four are…
Advisory committee recommends six of seven peptides for the 503A Bulks List, against FDA’s own proposal
FDA's reviewers proposed that none of the fourteen substances be added. The committee voted the other way on six of…
Five vantage points on one market. At the last one, a physician states the evidence gap and prescribes anyway.
A Bloomberg Businessweek feature followed research-use compounds from a testing laboratory to a consulting room. What changes across that distance…
Urolithin A extended life in worms and improved muscle in mice. No humans were studied.
The 2016 paper that made a gut-bacterial metabolite into a mitophagy target — and what it left open.
Retatrutide meets primary endpoint in two further Phase 3 trials
Eli Lilly reported topline results from TRIUMPH-2 and TRIUMPH-3, both of which met their primary endpoints at 80 weeks.
Andrew Huberman keeps BPC-157 in his fridge and says there is no published human trial of it.
Two of the most-heard voices in this space spent an hour on peptides. Most of it was about what the…
Access the ARC Platform
SEE THE BIGGER PICTURE THROUGH EVIDENCE.
Build deeper scientific understanding by connecting research, context and
interpretation,